1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This grant may no longer be accepting applications.
The description indicates applications may be closed. Check the funder's website to confirm availability before applying.
Visit funder's website →FDA Postdoctoral Fellowship in New Approach Methodologies (NAMs) (FDA-CDER-2026-0033) is sponsored by FDA Center for Drug Evaluation and Research (CDER). A research opportunity within the FDA Center for Drug Evaluation and Research (CDER), Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS). The focus is on new approach methodologies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Zintellect will be down from Saturday, August 15, at 3 a. m. through Sunday, August 16, at noon EDT.
Please plan accordingly. Thank you for your patience. FDA Postdoctoral Fellowship in New Approach Methodologies (NAMs) This opportunity is closed.
U.S. Food and Drug Administration (FDA) Connect with ORISE... on the GO! Download the new ORISE GO mobile app in the Apple App Store or Google Play Store to help you stay engaged, connected, and informed during your ORISE experience and beyond!
A complete application consists of: Transcripts – Click here for detailed information about acceptable transcripts A current resume/CV, including academic history, employment history, relevant experiences, and publication list One educational or professional recommendation All documents must be in English or include an official English translation. If you have questions, send an email to ORISE. FDA.
CDER@orau. org . Please include the reference code for this opportunity in your email.
4/30/2026 12:00:00 AM Eastern Time Zone *Applications will be reviewed on a rolling-basis. FDA Office and Location: A research opportunity is available within the Food and Drug Administration (FDA) in The Center for Drug Evaluation and Research (CDER), Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), located at Silver Spring, Maryland.
The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. These efforts cover more than just medicines.
Research Project: The participant will conduct research evaluating a lung microphysiological system (MPS) as a new approach methodology (NAM) to study the disposition of anti-infective drugs in the epithelial lining fluid (ELF). This project supports the FDA’s goal of integrating predictive, human-relevant models that enhance drug development and reduce animal testing.
Under the guidance of a mentor in the Division of Applied Regulatory Science (DARS), the participant will design and perform in vitro studies using the lung MPS to measure drug permeability and ELF concentration-time profiles. The participant will collaborate with interdisciplinary scientists to analyze results, compare MPS-derived profiles with clinical data, and assess translational concordance.
These efforts will include identifying factors that contribute to variability between in vitro and clinical outcomes and optimizing model performance. The participant will help prepare reports, presentations, and publications advancing the regulatory application of MPS technology and may join in developing reviewer tools, templates, and training materials to support the regulatory use of lung NAMs.
Learning Objectives: Under the guidance of a mentor, you will gain comprehensive training in lung MPS setup and maintenance, primary human cell culture, and drug permeability testing. You will receive instruction in quantitative analysis using LC-MS/MS, pharmacokinetic data interpretation, and the principles of drug absorption, distribution, metabolism, and excretion (ADME).
Participation in workshops, seminars, and discussions on MPS qualification and regulatory data integration will strengthen your scientific foundation. Through the program you will also improve your scientific writing, data presentation, and peer exchange skills to enhance communication and critical-thinking skills within a regulatory science setting. Mentor: The mentor for this opportunity is Shekh Rahman ( shekh.
rahman@fda. hhs. gov ).
If you have questions about the nature of the research, please contact the mentor. Anticipated Appointment Start Date: 2026. Start date is flexible and will depend on a variety of factors.
Appointment Length: The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds. Level of Participation: The appointment is full time. Citizenship Requirements : This opportunity is available to U.S. citizens and Lawful Permanent Residents (LPR) only.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program.
Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits. Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.
If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA.
For additional requirements, see FDA Ethics for Nonemployee Scientists . FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency.
This agreement covers such topics as the following: Non-employee nature of the ORISE appointment; Prohibition on ORISE Fellows performing inherently governmental functions; Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship; The fact that research materials and laboratory notebooks are the property of the FDA; ORISE fellow’s obligation to protect and not to further disclose or use non-public information.
The qualified candidate should be currently pursuing or have received a doctoral degree in the one of the relevant fields. Citizenship: LPR or U.S. Citizen Degree: Doctoral Degree received within the last 60 months or currently pursuing.
Chemistry and Materials Sciences ( 1 ) Life Health and Medical Sciences ( 51 ) Science & Engineering-related ( 1 ) I am a U.S. citizen, or I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.) I have read the FDA Ethics Requirements.
The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum! If you need assistance using this site, please send an email to Zintellect@orau. org .
Please rate your experience, and/or leave a comment. How would you rate your overall experience with Zintellect? You gave a rating of 0 star(s) This box is meant for feedback only.
Please direct questions to the program POC or zintellect@orau. org Security/Privacy Statement Close Security/Privacy Statement By continuing to use this system you indicate your awareness of and consent to the following terms and conditions of use. LOGOUT IMMEDIATELY if you do not agree to the conditions stated in this warning.
This system is part of a Federal information system. This system is monitored for security purposes to ensure it remains available to all users and to protect information in the system. The system employs software programs to monitor network traffic to identify unauthorized activities.
By accessing this system, you are expressly consenting to these monitoring activities.
Unauthorized attempts to defeat or circumvent security features; to use the system for other than intended purposes; to deny service to authorized users; to access, obtain, alter, damage, or destroy information; to upload or change information; to otherwise cause system or information damage; or otherwise to interfere with the system or its operation, is prohibited.
Evidence of such acts may be dis-closed to law enforcement authorities and result in prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996, or other applicable laws. This system is for authorized use only. Use of this system constitutes consent to security monitoring and testing.
All activity is logged with your host name and IP address. Users (authorized or unauthorized) have no explicit or implicit expectation of privacy. Any or all uses of this system and all files on this system may be intercepted, monitored, recorded, copied, audited, inspected, and dis-closed to authorized site and law enforcement personnel, as well as authorized officials of other agencies, both domestic and foreign.
By using this system, the user consents to such interception, monitoring, recording, copying, auditing, inspection, and disclosure at the discretion of authorized site or law enforcement personnel. Unauthorized or improper use of this system may result in administrative disciplinary action and civil and criminal penalties. Close Close Security/Privacy Statement You have been inactive on this page for .
You will be logged out after 03:00:00. Close Compatible Browsers Select an icon below to visit the website and download an appropriate browser. Close Close Compatible Browsers For help, please email Zintellect@orau.
org . Question: What is the deadline for submitting an application? Answer: Not all opportunities have application deadlines.
Some opportunities remain open until they are filled. If an opportunity has an application deadline, then it will be listed in the opportunity details or in the opportunity catalog. Question: How do I reset my password?
Answer: If you have forgotten your password or wish to reset your password, use the "Forgot password or username?" tab on the login to reset it. Question: I forgot my username.
How do I retrieve it? Answer: Use the "Forgot password or username?" tab on the login.
You will receive an email containing your username. Question: What do I need to submit an application? Answer: Typically, applicants are required to submit a resume or CV, an official copy of their transcripts or academic record, and a minimum of two references at the time they apply.
Additional requirements such as a writing sample, thesis or dissertation, etc. may be required. Review the opportunity details for additional information about the requirements for applying for an opportunity. Question: Where do I upload my transcripts?
Answer: If required, you will be asked to upload your transcript as a part of the application process. Question: Where do I submit a writing sample? Answer: If required, you will be asked to upload a writing sample as part of the application process.
Question: Can a family member serve as a reference? Answer: No; family members may not serve as references. References must be able to speak to your educational and/or professional experience.
At least one academic reference is preferred. Forgot password or username? Invalid or expired username or password.
You can try again or reset your password using the 'Forgot password or username?' tab above. Select an option below and enter the email address associated with your Zintellect account.
You will receive an email with additional information for your account. If you need additional assistance, please contact Zintellect Support . Invalid email.
Please try again. I forgot / need to reset my password Please select your appropriate user type Did the opportunity match? Close Did the opportunity match?
Our Zintellect A. I. is constantly learning how to Match you to our opportunities!
So, we want to know when we get it right or when we get it wrong. This will help us make our better! Plus, as a potential applicant to one of our many opportunities across the country, we value you and want to help you on your career path!
According to the current listing, eligibility includes: The qualified candidate should be currently pursuing or have received a doctoral degree in one of the relevant fields such as Chemistry and Materials Sciences, Engineering, Life Health and Medical Sciences, or Science &…. Confirm the full requirements in the official notice before applying.
FDA Postdoctoral Fellowship in New Approach Methodologies (NAMs) (FDA-CDER-2026-0033) is funded by FDA Center for Drug Evaluation and Research (CDER). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article